Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase II Study of Induction Treatment With Folfoxiri Plus Bevacizumab Followed by Preoperative Chemoradiotherapy Plus Bevacizumab in Patients With Locally Advanced, Resectable Rectal Cancer.

NCT03085992 is registered in ClinicalTrials.gov with Azienda Ospedaliero, Universitaria Pisana as lead sponsor.

NCT NCT03085992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03085992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase II Study of Induction Treatment With Folfoxiri Plus Bevacizumab Followed by Preoperative Chemoradiotherapy Plus Bevacizumab in Patients With Locally Advanced, Resectable Rectal Cancer.
Lead sponsor
Azienda Ospedaliero, Universitaria Pisana
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2012
Completion date
March 12, 2018
Enrollment
49 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer